
đ§Ź The "Respiration Model": Balancing Debate & Execution | Jacob Glanville Re-Release (Part 3/4)
"If you are capable of acquiring knowledge, of applying the knowledge, and you like it, you can succeed. It doesn't matter what it is." Weâre revisiting some of our previous episodes over the holidays this year. Our next re-release is this episode of The Biotech Startups Podcast, in which Jacob Glanville breaks down how he built Distributed Bio from a napkin-stage idea into a full-service antibody discovery platformâwithout traditional venture capital. He shares how creative partnerships with USFâs biotech masterâs program and a scrappy animal facility in Guatemala helped him access labs, talent, and proof-of-concept data, even as early setbacks with SuperHuman 1.0 cost him clients and sleep. The conversation then dives into the realities of scaling: squeezing into half a bench at JLABS before expanding into a 7,500-square-foot facility powered by smart equipment leasing and a growing team. Jacob also introduces his âRespiration Modelâ of leadershipâopen debate followed by uncompromising executionâand explains why rising competition and strong universal vaccine data led him to sell Distributed Bio to Charles River Laboratories and spin out Centivax just as the pandemic hit.
The Biotech Startups Podcast · Excedr
Audio is streamed directly from the publisher (media.fame.so) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
- Building Distributed Bio's business model: Software licensing, SuperHuman library development, and service contracts without VC funding
- Scrappy early-stage execution: USF grad student partnerships, Guatemala animal facility, and surviving SuperHuman 1.0's defects
- Scaling operations: JLABS growth, equipment leasing strategy, protocol standardization, and hiring 60-70 interns over multiple years
- The "Respiration Model": Balancing organic innovation with hierarchical execution, managing co-founder tensions, and creating culture
- Strategic exit and new chapter: CRO acquisition timing, competitive landscape analysis, and spinning out Centivax for universal vaccines
Subscribe to the Podcast: